Acadia Pharmaceuticals (ACAD) PT Raised to $19 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Goldman Sachs tech conference highlights AI spending outlook
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Acadia Pharmaceuticals (ACAD) IP Decision 'Removes a Key Overhang' - BMO Capital
May 16, 2025 11:56 AM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $24.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) saying the IP decision removes a key overhang for ACAD shares Into the 2030s.
The analyst commented, "Positive update for ACAD shares... More
Acadia Pharma (ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
May 16, 2025 10:08 AM EDTAcadia Pharma (NASDAQ: ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
... MoreAcadia Pharmaceuticals (ACAD) PT Raised to $26 at JPMorgan
May 16, 2025 8:49 AM EDTJPMorgan analyst Tessa Romero raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $25.00) while maintaining a Overweight rating.... More
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
May 14, 2025 4:07 AM EDTCitizens JMP analyst Jason Butler reiterated a Market Outperform rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst commented, Solid quarter with NUPLAZID continuing to excel and robust patient growth for DAYBUE; we reiterate our Market Outperform rating and $37 risk-adjusted, DCF-derived price... More
